A study to compare the efficiency of sterile talc, tetracycline and bleomycin as sclerosing agents for medical pleurodesis in the treatment of malignant pleural effusions

Not Applicable

Completed

• Conditions: Cancer; Malignant neoplasm without specification of site; Malignant pleural effusion

• Registration Number: ISRCTN35591640
• Lead Sponsor: Department of Health (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09-12
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Predominantly lung cancer patients with a selection of other cancer patients with malignancy effusions. (This is likely to be mostly breast cancer patients.)

Exclusion Criteria

Not provided at time of registration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study should provide information as to which of these most commonly used agents for medical pleurodesis is most effective in preventing further malignant pleural effusions. It should provide information on which agent if any is associated with more prolonged survival. It should provide information on issues such as pain and infection rates during pleurodesis with these agents. Hopefully, these data will lead to an evidence based choice of sclerosing agent for cancer patients with malignant pleural effusions.

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration